Skip to main content
. 2017 Aug 1;8(45):79825–79834. doi: 10.18632/oncotarget.19781

B) At the end of follow-up (median 37 months, n = 315).

Sensitivity Specificity PPV NPV Diagnostic accuracy
ATA 80,4 46,5 20,4 93,3 51,4
ETA 73,9 60,6 24,3 93,1 62,5
ATA after SPECT/CT 78,3 72,9 33,0 95,1 73,7
SPECT/CT 71,7 86,6** 47,8 94,7 84,4***
Risk at 1 year 100* 93,3** 71,9 100 94,3***

*No significant differences in sensitivities were found except in case of one-year reclassification (p < 0.01).

**Specificities of the individual parameters differed significantly, the one-year reclassification had the highest value (p < 0.01). The specificity of SPECT/CT was also significantly better than the values of the ATA and ETA risk classifications (p < 0.001).

***Diagnostic accuracy of one-year reclassification was excellent but not significantly better than that of SPECT/CT (p = 0.59). Both method provided better prediction than ATA, ETA and ATA after SPECT/CT classifications (p < 0.01).